A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participant
A phase 3 trial of Odronextamab, Lenalidomide, Rituximab in follicular lymphoma, run by Regeneron Pharmaceuticals, now recruiting.
Overview
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma is a phase 3 interventional study registered as NCT06149286 by Regeneron Pharmaceuticals, with 580 participants planned, started 2023-12-28 and due to reach its primary completion in 2031-04-30. Interventions recorded: Odronextamab, Lenalidomide, Rituximab. Conditions listed: Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL). No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TrialA Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy
Shares Odronextamab, Regeneron, Rituximab, Follicular lymphoma.
- TrialA Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemo
Shares Odronextamab, Regeneron, Rituximab, Follicular lymphoma.
- TrialA Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treat
Shares Odronextamab, Regeneron.
- TrialA Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomi
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TrialStudy of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease
Shares Lenalidomide, Rituximab, Follicular lymphoma.
- TrialA Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa
Shares Odronextamab, Regeneron, Rituximab.
- TrialA Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa
Shares Lenalidomide, Rituximab, Follicular lymphoma.